Peony and licorice decoction fumigation treatment for strephenopodia after stroke: study protocol for a randomized controlled pilot trial

注册号:

Registration number:

ITMCTR2000003253

最近更新日期:

Date of Last Refreshed on:

2020-04-28

注册时间:

Date of Registration:

2020-04-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

芍药甘草汤熏蒸治疗中风后足内翻:随机对照先导试验研究方案

Public title:

Peony and licorice decoction fumigation treatment for strephenopodia after stroke: study protocol for a randomized controlled pilot trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

芍药甘草汤熏蒸治疗中风后足内翻的探索性研究

Scientific title:

The clinical effect and biomechanical mechanisms of Peony and licorice decoction fumigation treatment for poststroke strephenopodia: a randomized controlled pilot trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000032433 ; ChiMCTR2000003253

申请注册联系人:

景城阳

研究负责人:

艾娟娟

Applicant:

Chengyang Jing

Study leader:

Juanjuan Ai

申请注册联系人电话:

Applicant telephone:

+86 13576265871

研究负责人电话:

Study leader's telephone:

+86 15010179928

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13576265871@163.com

研究负责人电子邮件:

Study leader's E-mail:

15010179928@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区海运仓5号

研究负责人通讯地址:

北京市东城区海运仓5号

Applicant address:

5 Haiyuncang, Dongcheng District, Beijing, China

Study leader's address:

5 Haiyuncang, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学东直门医院

Applicant's institution:

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

DZMEC-KY-2019-200

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学东直门医院伦理委员会

Name of the ethic committee:

Ethics Committee of Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/4/17 0:00:00

伦理委员会联系人:

商建伟

Contact Name of the ethic committee:

Jianwei Shang

伦理委员会联系地址:

北京市东城区海运仓5号

Contact Address of the ethic committee:

5 Haiyuncang, Dongcheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学东直门医院

Primary sponsor:

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市东城区海运仓5号

Primary sponsor's address:

5 Haiyuncang, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

具体地址:

东城区海运仓5号

Institution
hospital:

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

Address:

5 Haiyuncang, Dongcheng District

经费或物资来源:

北京中医药大学校级自主选题项目

Source(s) of funding:

University-level independent topic selection project of Beijing university of Chinese medicine

研究疾病:

中风后足内翻

研究疾病代码:

Target disease:

poststroke strephenopodia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过记录试验组和对照组中中风后足内翻患者生物力学指标和临床量表的变化,以客观数据的形式分析芍药甘草汤熏蒸治疗中风病足内翻的效果。

Objectives of Study:

By recording the change of biomechanical index and clinical scales of patients with poststroke strephenopodia in the experimental group and the control group, the effect of Peony and licorice decoction fumigation in the treatment of poststroke strephenopodia will be analyzed in the form of objective data.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 符合现代医学缺血性中风的诊断标准,并由CT或MRI检查证实; 2. 性别男女均可,年轻在35-75岁之间; 3. 首次发病或虽既往有中风病史但未遗留神经功能障碍(mRS≤2分); 4. 中风病发病后生命体征平稳开始至发病6个月以内的患者; 5. 本次发病具有足内翻症状,且能够独立行走6米以上; 6. 患者血压稳定在160/100mmHg以下; 7. 能够配合课题研究,简易智能精神状态检查MMSE≥24分; 8. 过去从未接受过熏蒸治疗; 9. 患者本人或其监护人同意参加研究并签署知情同意书。

Inclusion criteria

1. confirmed stroke patients with results from computed tomography (CT) or magnetic resonance imaging (MRI); 2. aged between 35 and 75 years, male or female; 3. first episode of stroke or with a history of stroke but with no serious neurofunctional disablility and modified Ranking Scale (mRS) grade <= 2; 4. stable condition after stroke and within 6 months of the duration; 5. with strephenopodia and be able to walk at least 6 meters; 6. blood pressure lower than 160/100 mmHG; 7. sufficient cognition to follow commands and Mini-Mental State Examination (MMSE) score >=24; 8. never used fumigation treatment before; 9. the patients or their legal guardian sign an informed consent.

排除标准:

1. 符合脑梗死诊断标准,但经过溶栓治疗的患者; 2. 符合脑梗死诊断标准,但发病超过半年的患者; 3. 蛛网膜下腔出血、脑出血、TIA、脑肿瘤、脑外伤等不符合诊断的患者; 4. 本次发病没有足内翻症状,或有足内翻症状但不能行走6米以上; 5. 中风后病情不稳定或病情趋于恶化及出现新的梗死或出血的患者; 6. 合并有腰椎病、膝骨关节病变、足部病变等其他能够影响患者行走步态的疾病; 7. 合并有严重的心、肺、肝、肾等重要脏器及血液系统功能异常的患者; 8. 伴有中重度认知理解或视力障碍,不能配合完成康复治疗及步态检查的患者; 9. 妊娠或哺乳期的妇女; 10. 正在参加其他临床研究的患者。

Exclusion criteria:

1. received surgery or thrombolytic therapy; 2. duration of stroke more than 6 months; 3. stroke without strephenopodia or with but could not walk 6 meters; 4. vital signs are not stable or with worsening conditions such like new infarction or bleeding; 5. combined with other cerebral diseases such as subarachnoid hemorrhage, cerebral hemorrhage, brain tumor, brain trauma and so on; 6. combined with lumbar vertebrae disease, knee joint disease, foot disease and other diseases that can affect the patient's walking gait; 7. combined with severe dysfunction of heart, lung, liver, kidney and blood system; 8. combined with moderate to severe cognitive comprehension or visual impairment that can affet rehabilitation treatment or gait examination; 9. pregnant or lactating women; 10. participating in other clinical trials.

研究实施时间:

Study execute time:

From 2019-01-01

To      2020-12-31

征募观察对象时间:

Recruiting time:

From 2020-06-01

To      2020-09-30

干预措施:

Interventions:

组别:

干预组

样本量:

95

Group:

Intervention group

Sample size:

干预措施:

芍药甘草汤熏蒸治疗+标准现代康复治疗

干预措施代码:

Intervention:

Peony and licorice decoction fumigation treatment and Standard modern rehabilitation treatment

Intervention code:

组别:

对照组

样本量:

95

Group:

Control group

Sample size:

干预措施:

安慰剂熏蒸治疗+标准现代康复治疗

干预措施代码:

Intervention:

placebo fumigation treatment and Standard modern rehabilitation treatment

Intervention code:

样本总量 Total sample size : 190

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

简化Fugl-Meyer运动功能评分法

指标类型:

次要指标

Outcome:

Fugl-Meyer Assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常生活活动能力量表

指标类型:

次要指标

Outcome:

Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良Ashworth量表

指标类型:

次要指标

Outcome:

Modified Ashworth Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Berg平衡量表

指标类型:

次要指标

Outcome:

Berg Balance Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑卒中专用生活质量量表

指标类型:

次要指标

Outcome:

Stroke-Specific Quality of Life Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

足跟内侧面积

指标类型:

主要指标

Outcome:

Medial planter area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 35
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

独立的第三方统计学人员将使用SPSS 25.0(IBM, USA)产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

The independent statistician will generate the randomization sequence using SPSS 25. 0 (IBM, USA).

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

我们将以论文的形式公布研究方案和结果。原始数据可以提供给有需要的科研工作者。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

We will publish the study protocol and research results in the form of papers. The original data can be provided to researchers who need it

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由病例记录表(Case Record Form, CRF)完成。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will collect and management data by Case Record Form (CRF).

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above